New Delhi, Jan 5: Bharat Biotech is set to launch the first-ever intranasal Covid vaccine in the month of March this year.
Bharat Biotech has proposed that the intranasal vaccine will be used as a third dose or a booster dose for the people who have been completely vaccinated with either Covaxine or Covishield while the interval between the second and the third dose must be six months.
According to sources, Bharat Biotech has aims to conduct a clinical trial of 5000 people before launching the vaccine in the Indian market.
Worth mentioning, Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) held a meeting earlier this week, on Tuesday to discuss the Bharat Biotech’s application for clinical trials of its intranasal Covid vaccine.
Meanwhile, The Government has recently approved Serum Institute of India’s vaccine Covovax, Biological E’s jab Corbevax and anti-Covid pill Molnupiravir.